Guardant Health, Inc. $GH Shares Acquired by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 47.7% during the first quarter, Holdings Channel reports. The firm owned 17,305 shares of the company’s stock after buying an additional 5,585 shares during the period. Illinois Municipal Retirement Fund’s holdings in Guardant Health were worth $1,598,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. V Square Quantitative Management LLC acquired a new position in Guardant Health during the 4th quarter valued at approximately $27,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health in the fourth quarter worth $31,000. Elyxium Wealth LLC bought a new stake in Guardant Health in the fourth quarter valued at $35,000. Parallel Advisors LLC lifted its stake in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the last quarter. Finally, Ascentis Independent Advisors acquired a new position in shares of Guardant Health during the first quarter valued at $38,000. Institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 100,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the sale, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. The trade was a 4.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Chris Freeman sold 24,406 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the completion of the sale, the insider directly owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. This represents a 28.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 708,565 shares of company stock worth $90,556,597 over the last ninety days. Insiders own 5.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Morgan Stanley upped their price target on shares of Guardant Health from $130.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Piper Sandler set a $127.00 target price on shares of Guardant Health in a research note on Thursday, May 21st. Wolfe Research began coverage on shares of Guardant Health in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 target price for the company. Sanford C. Bernstein upped their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, July 2nd. Finally, BTIG Research raised their price target on shares of Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and a consensus target price of $160.04.

Guardant Health Stock Performance

Shares of GH opened at $152.29 on Wednesday. The firm has a market capitalization of $20.19 billion, a price-to-earnings ratio of -44.92 and a beta of 1.59. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08. The stock’s fifty day moving average is $136.28 and its 200-day moving average is $111.01.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.